SBI ALApromo Co., Ltd.
Notice Regarding the Acquisition of SBI Pharmaceuticals’ Supplement Business
SBI ALApromo Co., Ltd. (headquartered in Tokyo), a subsidiary of SBI Holdings Co., Ltd., manufactures and sells health foods and cosmetics using 5-aminolevulinic acid phosphate (*1 below, “5-ALA”). Minato-ku, Representative Director: Yasushi Takezaki, hereinafter “SBI ALApromo”) announced today that at its board of directors meeting, SBI
Pharmaceuticals Co., Ltd. (Headquarters: Minato-ku, Tokyo, President and CEO: Yoshitaka Kitao, hereinafter “SBI Pharma”) ), we have resolved to take over the supplement business, which is part of the business of ), through a company split (absorption-type split) on February 21, 2023 (planned). As a result of this company split, SBI ALApromo will be responsible for all operations related to the supplement business in the future.
Until now, SBI ALApromo has been engaged in the supplement business centered on its own brand of food with functional claims, but will also focus on developing supplements of other companies’ brands. In addition, we will promote business development for the global market, such as developing overseas business in cooperation with group companies that operate supplement business using 5-ALA based in Europe and the United States.
■ Company split schedule
Contract date: December 16, 2022
Effective date: February 21, 2023 (planned)
We ask for your continued support for the SBI Group’s 5-ALA business, including pharmaceuticals and supplements.
(*1) 5-Aminolevulinic acid phosphate (5-ALA) has been added to the Ministry of Health, Labor and Welfare’s list of essential ingredients (ingredients) that are not judged to be pharmaceuticals unless they claim pharmaceutical efficacy and effects. It is not a pharmaceutical ingredient.
Details about this release: